Day One Biopharmaceuticals, LLC

After the explosive increase in the obesity market size led by GLP-1 agonist therapies in the last few years, the natural question is: what will biopharma’s next big growth markets be? Scrip has int

Ipsen is making good progress in reducing its reliance on the acromegaly and neuroendocrine tumour blockbuster Somatuline, according to CEO David Loew who has heralded the launches of two rare disease

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp

It has been less than three years since Atlas Venture closed its thirteenth venture capital fund and one thing is unchanged with its fourteenth – the size of the fund. Atlas announced on 5 December th